Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
501 Survival and immune response data from intratumoral INT230–6 alone (IT-01) and with pembrolizumab [KEYNOTE-A10] in subjects with locally advanced, unresectable and metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.